Gastroenterologia: impacto das terapias biológicas no controle da doença de Crohn em adolescentes
DOI:
https://doi.org/10.18378/rebes.v14i3.10789Abstract
This article reviewed the use of biological therapies in the management of Crohn's Disease in adolescents, a chronic inflammatory condition of the gastrointestinal tract that requires interventions to prevent long-term complications. The problem addressed was the evaluation of the efficacy and safety of biological therapies, considering the need for treatments that can induce and maintain disease remission, improve quality of life, and reduce associated complications. Therefore, the objectives of this study included the analysis of the different available biological therapies, the comparison of their efficacies and safety profiles, and the evaluation of the impact of these therapies on the quality of life of adolescents. To achieve this, the adopted methodology was a literature review, involving clinical studies and systematic reviews published in major scientific databases. The results obtained indicated that biological therapies, such as tumor necrosis factor inhibitors, integrin antagonists, and interleukin inhibitors, demonstrated efficacy in inducing and maintaining remission, in addition to improving the quality of life of adolescent patients. Infliximab, adalimumab, and certolizumab pegol were effective in reducing inflammatory activity, with infliximab being the first to mark a new era in the treatment of Crohn's Disease. Vedolizumab and ustekinumab provided additional options with favorable safety profiles, especially important for adolescents undergoing prolonged treatment.
Downloads
References
ADEGBOLA, S. O. et al. Anti-TNF therapy in Crohn’s disease. International journal of molecular sciences, v. 19, n. 8, p. 2244, 2018.
ATTAUABI, M. et al. Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease–a real-world two-center cohort study. European journal of gastroenterology & hepatology, v. 33, n. 1S, p. e709-e718, 2021.
BOYAPATI, R.; SATSANGI, J.; HO, G. Pathogenesis of Crohn's disease. F1000prime reports, v. 7, 2015.
CHERRY, L. N. et al. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn’s disease. Therapeutic advances in chronic disease, v. 6, n. 5, p. 224-233, 2015.
COHEN, R. D. BIOLOGICAL THERAPY IN CROHN’S DISEASE 24. The Stem Cell Microenvironment and its Role in Regenerative Medicine and Cancer Pathogenesis, p. 329, 2016.
COLOMBEL, J. et al. Vedolizumab, adalimumab, and methotrexate combination therapy in crohn’s disease (EXPLORER). Clinical Gastroenterology and Hepatology, v. 22, n. 7, p. 1487-1496. e12, 2024.
COSKUN, M.; VERMEIRE, S; NIELSEN, O. Novel targeted therapies for inflammatory bowel disease. Trends in pharmacological sciences, v. 38, n. 2, p. 127-142, 2017.
CUSHING, K.; HIGGINS, P. Management of Crohn disease: a review. Jama, v. 325, n. 1, p. 69-80, 2021.
CUSHING, K.; HIGGINS, P. Management of Crohn disease: a review. Jama, v. 325, n. 1, p. 69-80, 2021.
DANESE, S.; VUITTON, L.; PEYRIN-BIROULET, L. Biologic agents for IBD: practical insights. Nature reviews Gastroenterology & hepatology, v. 12, n. 9, p. 537-545, 2015.
FEUERSTEIN, J. D.; CHEIFETZ, A. S. Crohn disease: epidemiology, diagnosis, and management. In: Mayo Clinic Proceedings. Elsevier, 2017. p. 1088-1103.
FLORES, F. da S.; RICALCATI, C. da S.; BOETTCHER, S. Fistulização de parede abdominal peri-ileostomia em adolescente com doença de Crohn severa: estudo de caso. Clinical and biomedical research. Porto Alegre, 2020.
FLORHOLMEN, J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology, v. 50, n. 1, p. 43-52, 2015.
GAJENDRAN, M. et al. A comprehensive review and update on Crohn's disease. Disease-a-month, v. 64, n. 2, p. 20-57, 2018.
HA, F.; KHALIL, H. Crohn’s disease: a clinical update. Therapeutic advances in gastroenterology, v. 8, n. 6, p. 352-359, 2015.
HANSEN, T.; TAR/GOWNIK, L. E. Ustekinumab for the treatment of Crohn’s disease. Expert Review of Gastroenterology & Hepatology, v. 10, n. 9, p. 989-994, 2016.
KOTZE, P. G. et al. Clinical utility of ustekinumab in Crohn’s disease. Journal of inflammation research, p. 35-47, 2018.
LUZENTALES, M. et al. Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Frontiers in Cell and Developmental Biology, v. 9, p. 612830, 2021.
MACHADO, K. do E. S. et al. Aspectos sociodemográficos e clínicos relacionados à doença de Crohn em adolescentes. Enfermagem em Foco, v. 12, n. 5, 2021.
MATTOS, B. R.et al. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators of inflammation, v. 2015, n. 1, p. 493012, 2015.
MCLEAN, L. P.; CROSS, R. K. Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease. Expert opinion on investigational drugs, v. 25, n. 3, p. 263-273, 2016.
OLESEN, C. M. et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology & therapeutics, v. 159, p. 110-119, 2016.
PASCAL, V. et al. A microbial signature for Crohn's disease. Gut, v. 66, n. 5, p. 813-822, 2017.
REVOREDO, C. M. S. et al. Doença de Crohn e probióticos: uma revisão. Revista da Associação Brasileira de Nutrição-RASBRAN, v. 8, n. 2, p. 67-73, 2017.
RODA, G. et al. Crohn’s disease. Nature Reviews Disease Primers, v. 6, n. 1, p. 22, 2020.
SINGH, S. et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. The Lancet Gastroenterology & Hepatology, v. 6, n. 12, p. 1002-1014, 2021.
SULZ, M. C. et al. Treatment algorithms for Crohn’s disease. Digestion, v. 101, n. Suppl. 1, p. 43-57, 2020.
TORRES, J. et al. Crohn's disease. The Lancet, v. 389, n. 10080, p. 1741-1755, 2017.
TRINDADE, M.; MORCERF, C. C. P; ESPASANDIN, V. L. Terapia biológica na doença de Crohn: quando iniciar?. Revista da Sociedade Brasileira de Clínica Médica, v. 17, n. 1, p. 41-46, 2019.
TUN, G. S. Z; LOBO, A. J. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn’s disease. Expert Opinion on Drug Metabolism & Toxicology, v. 11, n. 2, p. 317-327, 2015.
VANDE, N.; GILS, A. Pharmacokinetics of anti‐TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. The Journal of Clinical Pharmacology, v. 55, n. S3, p. S39-S50, 2015.
VEAUTHIER, B.; HORNECKER, J. R. Crohn's disease: diagnosis and management. American family physician, v. 98, n. 11, p. 661-669, 2018.
VENITO, L. S; SANTOS, M. S. B; FERRAZ, A. R Doença de Crohn e retocolite ulcerativa. Revista Eletrônica Acervo Saúde, v. 15, n. 7, p. e10667-e10667, 2022.
VERSTOCKT, B. et al. New treatment options for inflammatory bowel diseases. Journal of gastroenterology, v. 53, p. 585-590, 2018.
WEHKAMP, J. et al. Inflammatory bowel disease: Crohn’s disease and ulcerative colitis. Deutsches Ärzteblatt International, v. 113, n. 5, p. 72, 2016.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Felipe Maia da Fonsêca, Daniel Duarte Dantas Moura , Maria Isabel Teles Nogueira , Marjorie Correia de Andrade, Luíza Maria Oliveira Cavalcante , Beatris Rabelo Maia , Victor Sarmento Coelho, Gabriela Candida de Albuquerque
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Termo de cess